Dr. Milind Desai discusses the design and results of the VALOR-HCM trial, which demonstrated that mavacamten reduced the need for septal reduction therapy at 16 weeks in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
ReachMD
Be part of the knowledge.™Cardiac Myosin Inhibitor Reduces Need for Septal Reduction Therapy in Obstructive HCM
Choose a format
Media formats available:
Facebook Comments